Aucubin slows the development of osteoporosis by inhibiting osteoclast differentiation via the nuclear factor erythroid 2-related factor 2-mediated antioxidation pathway

Yongfeng Zhang, Xin Liu, Yangyang Li, Minkai Song, Yutong Li, Anhui Yang, Yaqin Zhang, Di Wang & Min Hu
Osteoporosis (OP) is a metabolic disease. We have previously demonstrated that aucubin (AU) has anti-OP effects that are due to its promotion of the formation of osteoblasts. To investigate the mechanisms of anti-OP effects of AU. C57BL/6 mice were randomly divided into control group, 30 mg/kg Dex-induced OP group (OP model group, 15 μg/kg oestradiol-treated positive control group, 5 or 45 mg/kg AU-treated group), and 45 mg/kg AU-alone-treated group. The administration lasted for 7 weeks....
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.